IN VITRO METHOD FOR THE DIAGNOSIS AND IDENTIFICATION OF THE CLINICAL STATE OF MULTIPLE SCLEROSIS

Description

The diagnosis of Multiple Sclerosis (MS) is complex, and currently, there is no specific biomarker available. Likewise, there are no markers that allow for the prediction of disease progression. This invention proposes the identification of a series of serum proteins and alternative RNA splicing isoforms in peripheral blood mononuclear cells from patients with Multiple Sclerosis, which would facilitate diagnosis (discriminating between MS patients and healthy controls) and differential diagnosis with other inflammatory neurological diseases (OIND). Additionally, some of these markers are associated with disease progression, allowing discrimination between patients with relapsing-remitting, secondary progressive, and primary progressive forms.

Advantages

The detected biomarkers:
• Contribute to the diagnosis and differential diagnosis of multiple sclerosis
• Are associated with disease activity
• Identification is performed in serum and blood cells, making the method minimally invasive for the patient
• The detection techniques are easily implementable in any clinical laboratory practice

Uses and Applications

The application of the invention is in the field of medicine, specifically in the diagnosis and prognosis of patients with multiple sclerosis, which has a prevalence in Spain of 100 per 100,000 inhabitants, with 2,500–3,000 new cases diagnosed each year.
This invention facilitates the diagnosis and prognosis of the disease through markers obtained from blood.